Bml, Inc.

Other

National Hospital Organization Kinki-Chuo Chest Medical Center

Azbio Corporation

National Hospital Organization

Okada, Masaji

Takamori, Yasushi

Kazuyuki Ogawa

Kinya Nagata

Syoichi Takano

Kazuya Tanaka

Masaji Okada

Yasushi Takamori

Hiroyuki Hirai

Shoichi Takano

(Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

Therapeutic agent for infections, and treatment method using same

Therapeutic agent for infections, and treatment method using the same

An object of the present invention is to provide a method of identifying a substance which acts on a newly found second human prostaglandin Dreceptor subtype that differs from the DP receptor, and is useful for treating or preventing various diseases. In order to attain the object, the present invention provides a method of identifying properties of a test substance with respect to a human prostaglandin D receptor, by establishing correlation between the effect of a test substance on human CRTH2 with the effect of the test substance on the human prostaglandin D receptor.

Method of identifying properties of substance with respect to human prostaglandin D2 receptors

The present specification provides a means for specifying the condition and type of immune-related diseases on the basis of knowledge about the polarization of the distribution of helper T-cell subsets Th1 and Th2. More specifically, the gene (B19), specific only to the human Th2, is prepared by a subtraction method. A human-Th2-specific protein which the gene encodes is produced by recombinant methods, and a monoclonal antibody against the Th2-specific protein and a hybridoma which produces the monoclonal antibody is provided.

Monoclonal antibody which binds to a human-Th2-specific protein and

Human Th2 specific protein

An element for specifying the condition and type of immune-related diseases on the basis of the knowledge about the polarization of distribution of Th1/Th2 subsets of helper T cells. The element for specifying or correcting the polarization of the Th1/Th2 subsets is implemented by use of a recombinant vector, a transformant, a human-Th1-specific protein, and an antibody which uses the human-Th1-specific protein as an antigen. A human-Th1-specific gene is prepared and specified by a subtraction technique and is incorporated into the recombinant vector. The transformant is formed by transforming the recombinant vector. The Th1-specific protein is encoded by the gene derived from the transformant.

Human-Th1-specific protein, gene encoding the protein, transformants,

Growing community of inventors

Saitama, Japan

Kazuyuki Ogawa